Marcelo Garrido
LightNews LightNews
banner
drmarcelogarrido.bsky.social
Marcelo Garrido
@drmarcelogarrido.bsky.social
16 followers 19 following 14 posts
My passion is Gastrointestinal Oncology, high quality clinical trials, cancer biomarkers research, immunotherapy, ADC and the application of precision oncology.
Posts Replies Media Videos
drmarcelogarrido.bsky.social
www.youtube.com/watch?v=nLF-...
Cáncer gástrico es la primera causa de muerte en hombres en Chile
YouTube video by 24 Horas - TVN Chile
www.youtube.com
September 14, 2025 at 8:51 PM
drmarcelogarrido.bsky.social
ESMO GI 2025. Fantastic congress in amazing city, Barcelona. #orgulloSAGA #ESMO #ciudadBarcelona
July 2, 2025 at 8:27 AM
drmarcelogarrido.bsky.social
Fantastic result!. Best option for our patients. #ASCO25 #orgulloSAGA
June 1, 2025 at 1:46 PM
drmarcelogarrido.bsky.social
www.nejm.org/doi/full/10....
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | NEJM
On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal junctio...
www.nejm.org
May 31, 2025 at 3:37 PM
drmarcelogarrido.bsky.social
Thank you SAGA. Fantastic Clinical Trial Center in amazing meeting. #ASCO25
May 30, 2025 at 5:46 PM
drmarcelogarrido.bsky.social
Understanding how we get sick, for example gastric cancer. www.science.org/doi/10.1126/...
From North Asia to South America: Tracing the longest human migration through genomic sequencing
Genome sequencing of 1537 individuals from 139 ethnic groups reveals the genetic characteristics of understudied populations in North Asia and South America. Our analysis demonstrates that West Siberi...
www.science.org
May 18, 2025 at 2:28 PM
drmarcelogarrido.bsky.social
Precision Oncology !
www.onclive.com/view/fda-gra...
FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression
The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.
www.onclive.com
May 15, 2025 at 1:02 AM
drmarcelogarrido.bsky.social
ADC year !!
www.astrazeneca.com/media-centre...
Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breas...
www.astrazeneca.com
May 8, 2025 at 12:23 AM
drmarcelogarrido.bsky.social
www.thelancet.com/journals/lan...
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including the final overall survival data and patient-reported outcomes, will help to further characterise the potential clinical benefits of durvalumab plus bevacizumab plus TACE in hepatocellular carcinoma amenable to embolisation.
www.thelancet.com
January 11, 2025 at 10:31 AM
drmarcelogarrido.bsky.social
www.nejm.org/do/10.1056/N...
Anew confirmation of IO in MSI CRC.
Nivolumab plus Ipilimumab in Colorectal Cancer | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Nivolumab plus Ipilimumab in Colorectal Cancer
www.nejm.org
November 30, 2024 at 10:34 PM
drmarcelogarrido.bsky.social
Fantastic information
November 23, 2024 at 3:33 AM
drmarcelogarrido.bsky.social
www.fda.gov/drugs/resour...
November 23, 2024 at 3:18 AM
drmarcelogarrido.bsky.social
Journals Cancers Volume 12 Issue 7 10.3390/cancers12071863
November 23, 2024 at 2:27 AM
drmarcelogarrido.bsky.social
Gastric Cancer genomic profile is different in LaTam.
November 23, 2024 at 2:23 AM